STALEVO 125/31.25/200 levodopa/carbidopa (as monohydrate)/entacapone  tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

stalevo 125/31.25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 125 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 75/18.75/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

stalevo 75/18.75/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 75 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 200/50/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

stalevo 200/50/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 200 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 150/37.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

stalevo 150/37.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 150 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

stalevo 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 100 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.